PubHawk
October 2022 PMID 36260549

Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis.

Lisa Scarton, Ara Jo, Zhigang Xie, LaToya J O'Neal, Juan M Munoz Pena, Thomas J George, Jiang Bian

Download social card

Mentions

9
Peak: 6 in Oct 2022
across 3 sources since Oct 2022

Extended reach

38,458
potential audience

Total likes

675

Video views

33,309

Mentions per month

Oct 2022 – Jan 2024

Where it's discussed

  • X / Twitter6 posts
  • News2 articles
  • YouTube1 videos

AI synopsis

What people are saying

These discussions highlight the article's main conclusion that metformin use improves survival regardless of dose, with examples including mentions of particular cancer types like pancreatic and breast cancer. The tone varies from factual sharing with hashtags to brief summaries, demonstrating interest but limited critical engagement.

AgreementStrong agreement

Most discussions agree that metformin is associated with increased survival in older adults with advanced cancer, emphasizing the positive findings.

InterestModerate interest

While the topic is relevant to cancer treatment and pharmacology, the posts mainly share summaries and hashtags, indicating moderate interest.

EngagementModerate engagement

Posts cite the study and its implications, but lack deep analysis or critique, reflecting moderate engagement.

ImpactHigh impact

The focus on survival benefits and widespread sharing of various cancer types suggests a recognition of significant clinical impact.

Abstract in brief

  • This study explores how different doses of metformin, a common medication for type 2 diabetes, relate to survival rates in older adults with advanced (stage IV) cancers like lung, breast, colorectal, prostate, and pancreatic cancer.
  • The researchers found that patients using metformin generally had better overall survival compared to those who did not, regardless of the dose they took, although no significant difference was observed between higher and lower doses of metformin.
  • Overall, metformin use is linked to increased survival in older adults with stage IV cancer, but the specific dose (whether above or below 1000 mg daily) doesn't significantly change that benefit.
Read the full abstract

Top posts

Most liked on X and Bluesky
Orlando_uy
@Orlando_uy · X

Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis. Metformin use regardless of dose is associated with increased overall survival in older adults with stage IV cancer. https://t.co/r5SHFTpLWB

Oct 21, 2022 · 1 like · 694 followers View post →
Paperbirds_Oncology
@PaperbirdsO · X

New article: Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis https://t.co/ibUxaV1lZc #colorectalcancer #oncology https://t.co/JMLANlPMMU

Oct 19, 2022 · 891 followers View post →
Paperbirds_Oncology
@PaperbirdsO · X

New article: Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis https://t.co/usMPegDBzz #pancreaticcancer #oncology https://t.co/lttDfeQ6ay

Oct 21, 2022 · 891 followers View post →
Paperbirds_Oncology
@PaperbirdsO · X

New article: Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis https://t.co/gCzekBvegq #breastcancer #oncology https://t.co/QzXql4A6mt

Oct 19, 2022 · 891 followers View post →
Paperbirds_Oncology
@PaperbirdsO · X

New article: Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis https://t.co/WKgbjbdDNb #lungcancer #oncology https://t.co/0RvNSikhRN

Oct 19, 2022 · 891 followers View post →
Paperbirds_Oncology
@PaperbirdsO · X

New article: Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis https://t.co/5WE6YXwWKt #prostatecancer #oncology https://t.co/rvTrAb5roc

Oct 19, 2022 · 891 followers View post →

All mentions

Orlando_uy
@Orlando_uy · X

Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis. Metformin use regardless of dose is associated with increased overall survival in older adults with stage IV cancer. https://t.co/r5SHFTpLWB

Oct 21, 2022 · 1 like · 694 followers View post →
Paperbirds_Oncology
@PaperbirdsO · X

New article: Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis https://t.co/usMPegDBzz #pancreaticcancer #oncology https://t.co/lttDfeQ6ay

Oct 21, 2022 · 891 followers View post →
Paperbirds_Oncology
@PaperbirdsO · X

New article: Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis https://t.co/gCzekBvegq #breastcancer #oncology https://t.co/QzXql4A6mt

Oct 19, 2022 · 891 followers View post →
Paperbirds_Oncology
@PaperbirdsO · X

New article: Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis https://t.co/WKgbjbdDNb #lungcancer #oncology https://t.co/0RvNSikhRN

Oct 19, 2022 · 891 followers View post →
Paperbirds_Oncology
@PaperbirdsO · X

New article: Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis https://t.co/5WE6YXwWKt #prostatecancer #oncology https://t.co/rvTrAb5roc

Oct 19, 2022 · 891 followers View post →
Paperbirds_Oncology
@PaperbirdsO · X

New article: Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis https://t.co/ibUxaV1lZc #colorectalcancer #oncology https://t.co/JMLANlPMMU

Oct 19, 2022 · 891 followers View post →